Monfardini S, Tancini G, DeLena M, Villa E, Valagussa P, Bonadonna G
Med Pediatr Oncol. 1977;3(1):67-74. doi: 10.1002/mpo.2950030110.
In stage IV non-Hodgkin's lymphomas, CVP (cyclophosphamide, vincristine, and prednisone) was randomly compared to ABP (adriamycin, bleomycin, and prednisone). Of 62 patients entered into the study, 57 (CVP 27, ABP 30) were considered evaluable for comparison. In patients with liver and/or marrow involvement a second biopsy was performed to define complete remission (CR). CR occurred in 48% of patients treated with CVP and in 50% of those given ABP. The median duration of CR was 10.5 and 20.5 months, respectively. The difference is not statistically significant. Also, the survival of complete responders was not significantly different between the two treatment groups. After cross-over, secondary treatment with CVP produced an overall response rate of 40% (six of 15), compared to 50% (six of 12) obtained with ABP. In the ABP group, four patients developed a reversible interstitial penumonia. In two other patients, cardiomyopathy (fatal in one) was observed. In conclusion, although complete remission was similar in both groups, cumulative toxicity occurred in few patients given ABP. However, this combination could represent an effective alternative treatment to be used either in CVP failures or sequence with CVP.
在IV期非霍奇金淋巴瘤中，将CVP（环磷酰胺、长春新碱和泼尼松）与ABP（阿霉素、博来霉素和泼尼松）进行了随机对照研究。在进入该研究的62例患者中，57例（CVP组27例，ABP组30例）被认为可用于比较。对于有肝脏和/或骨髓受累的患者，进行了第二次活检以确定完全缓解（CR）。接受CVP治疗的患者中48%达到CR，接受ABP治疗的患者中50%达到CR。CR的中位持续时间分别为10.5个月和20.5个月。差异无统计学意义。此外，两个治疗组中完全缓解者的生存率也无显著差异。交叉治疗后，CVP作为二线治疗的总体缓解率为40%（15例中的6例），而ABP为50%（12例中的6例）。在ABP组中，4例患者发生了可逆性间质性肺炎。在另外2例患者中，观察到心肌病（1例死亡）。总之，虽然两组的完全缓解情况相似，但接受ABP治疗的少数患者出现了累积毒性。然而，这种联合方案可能是一种有效的替代治疗方法，可用于CVP治疗失败的患者或与CVP序贯使用。
